Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Kopran Ltd

KOPRAN.NS ✓ COMPLIANTFree checks used up today ☆ Track — members

NSE · Healthcare · Pharmaceuticals ·

India Micro Cap Analyst: N/A

Last Close

$2.80

▲ +6.14%

Market Cap $135.44M · Vol 504.15K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

32.41

FWD: N/A

Market Cap

$135.44M

Micro Cap

Div Yield

1.13%

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

44.76

Momentum

Beta

1.33

vs Market

52W High

$3.13

9.07% below

52W Low

$1.13

147.13% above

Volume

504.15K

Avg 555.66K

P/B

0.98

Price-to-book

ROE

N/A

Return on equity

Free Float

53.49%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Kopran Ltd (KOPRAN.NS) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does KOPRAN.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.07%

-1.46%

+35.16%

+63.01%

YTD

+76.01%

+60.95%

-0.40%

+18.54%

Financials & Valuation

TTM · Annual

Total Revenue	$72.91M
Net Income	$2.75M
Revenue Growth (YoY)	+79.17%
Gross Margin	27.59%
Operating Margin	8.87%
Net Profit Margin	3.78%
ROE	N/A
ROA · ROIC	3.92% · 4.80%

P/E Ratio	32.41
Forward P/E (FY1)	N/A
PEG Ratio	-0.61
P/S	0.76
P/B	0.98
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	48.33M

Technical Indicators

50-Day SMA	$2.68
200-Day SMA	$1.95
RSI (14)	44.76
Beta	1.33
52-Week High	$3.13
52-Week Low	$1.13

Volume Today	504.15K
Avg Daily Volume (30D)	555.66K
Relative Volume	0.91x
Volatility (10D)	52.17
Volatility (30D)	58.51
Free Float	53.49%

Analyst Consensus

N/A

Current Price $2.80

Mean Target N/A

52W Low$1.13 52W High$3.13

Current

Target

$1.13 $3.13

Current Analyst target

· 0 analysts

Identifiers

ExchangeNSE

FIGIBBG001S83WG8

ISININE082A01010

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Company -3.76% JNJ Johnson & Johnson -1.45% ABBV AbbVie Inc. -2.24% NVS Novartis AG -1.85% NOVN.S Novartis AG -0.10%

Company Profile

Kopran Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (API). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include amoxycillin, ampicillin, cloxacillin, amoxy clauv, flucloxacillin, and phenoxy methyl penicillin. Its non-penicillin-based finished oral dosage forms include macrolides, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management, gastroenterology, and respiratory. It has a portfolio, producing over 100 dosage forms. These include tablets, capsules, dry powder, suspension and injectables. Its subsidiary, Kopran Research Laboratories Ltd, manufactures a range of APIs, including Atenolol and Sterile Carbapenems.